Report
← Signal Board

VYNE Therapeutics financial statements

NASDAQ:VYNE · Nasdaq · Healthcare
$28.56+0.00%
2026-07-29 close

VYNE Therapeutics's published financial data is dated 2026-10-04. 2024 revenue was $1M. 2024 operating profit was −$44M.

Reported results

Financial safety

Reference indicatorAs of 2024
Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' -31.45
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
-31.45
Beneish M-Score
-2.72

No statistical flag

Sloan accrual
-8.76%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

2/9Weak

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score2/9

Profitability

  • Positive ROANot passed
  • Positive OCFNot passed
  • Improving ΔROANot passed
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtNot passed
  • Higher current ratioNot passed
  • No new sharesNot passed

Efficiency

  • Higher gross marginNot passed
  • Higher asset turnoverPass

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Revenue qualityDanger

매출 흑자인데 영업CF 적자 (OCF/매출 -6781%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Margin trendWarning

영업이익률 악화 (-6900.5% → -8710.0%, -1809.5%p). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
-8,710%
Interest coverage
-11.5x
Return on equity (ROE)
-76.5%

Operating margin −5pp

Operating loss
Interest coverageBase -11.5x adverse case -11.5x
Return on equity (ROE)Base -76.5% adverse case -91.1%

Revenue −15%

Interest coverage risk
Interest coverageBase -11.5x adverse case -9.8x
Return on equity (ROE)Base -76.5% adverse case -78.5%

Interest rate +2pp

Interest coverage risk
Interest coverageBase -11.5x adverse case -10.6x
Return on equity (ROE)Base -76.5% adverse case -91.6%

Interest coverage limit

Already below the limit by 9,469.1pp

Interest coverage limit at an operating margin of 759.1%

Interest expense coverage threshold

VYNE Therapeutics notifications

Quantus Signal · live data · not investment advice · Privacy Policy